I Küster1, C Rudack2, A Beule2,3. 1. Klinik für Hals‑, Nasen- und Ohrenheilkunde, Universitätsklinikum Münster, Kardinal-von-Galen-Ring 10, 48155, Münster, Deutschland. inga.kuester@ukmuenster.de. 2. Klinik für Hals‑, Nasen- und Ohrenheilkunde, Universitätsklinikum Münster, Kardinal-von-Galen-Ring 10, 48155, Münster, Deutschland. 3. Klinik und Poliklinik für Hals-Nasen-Ohrenkrankheiten, Kopf- und Halschirurgie, Universitätsmedizin Greifswald, Sauerbruchstraße, 17475, Greifswald, Deutschland.
Abstract
BACKGROUND: The spectrum of rhinological diseases is wide, as is that of their drug-based treatment. Only 1272 compounds coded R01 (nasal preparations) are listed in the ATC group (Anatomical Therapeutic Chemical Classification). Conservative therapy of rhinological diseases additionally includes systemic (often oral) application of corticosteroids, antibiotics and immunomodulators. OBJECTIVE: The aim of this paper is to outline possible complications of medication (subdivided into classes of ingredients) commonly used to treat rhinological diseases in hospitals. Useful therapeutic and preventive measures will be presented. MATERIALS AND METHODS: Based on the expert information in the current pharmacological drug index (ATC) for the R01 group as well as literature research in the PubMed, Cochrane Library and MEDLINE databases, medication used for the treatment of rhinological diseases was analysed in terms of side effects and their frequency. RESULTS: Common side effects of intranasally applied medication are local irritations, burning, dryness and epistaxis. Orally or intravenously applied rhinological medication can affect the organs and lead to side effects such as cardiac dysrhythmia or alterations of the blood count. It is recommended that the therapeutic be selected on an individual basis and that the patient be thoroughly informed about possible side effects. CONCLUSION: Particularly when treating children or pregnant or breastfeeding women, the indications of all nasal preparations should be checked carefully. The huge variety of rhinologicals enables an optimal individual selection on the basis of consideration of known side effects.
BACKGROUND: The spectrum of rhinological diseases is wide, as is that of their drug-based treatment. Only 1272 compounds coded R01 (nasal preparations) are listed in the ATC group (Anatomical Therapeutic Chemical Classification). Conservative therapy of rhinological diseases additionally includes systemic (often oral) application of corticosteroids, antibiotics and immunomodulators. OBJECTIVE: The aim of this paper is to outline possible complications of medication (subdivided into classes of ingredients) commonly used to treat rhinological diseases in hospitals. Useful therapeutic and preventive measures will be presented. MATERIALS AND METHODS: Based on the expert information in the current pharmacological drug index (ATC) for the R01 group as well as literature research in the PubMed, Cochrane Library and MEDLINE databases, medication used for the treatment of rhinological diseases was analysed in terms of side effects and their frequency. RESULTS: Common side effects of intranasally applied medication are local irritations, burning, dryness and epistaxis. Orally or intravenously applied rhinological medication can affect the organs and lead to side effects such as cardiac dysrhythmia or alterations of the blood count. It is recommended that the therapeutic be selected on an individual basis and that the patient be thoroughly informed about possible side effects. CONCLUSION: Particularly when treating children or pregnant or breastfeeding women, the indications of all nasal preparations should be checked carefully. The huge variety of rhinologicals enables an optimal individual selection on the basis of consideration of known side effects.
Entities:
Keywords:
Antibacterial agents; Corticosteroids; Drug therapy; Immunomodulation; Pharmacologic actions
Authors: M Archontaki; E K Symvoulakis; J K Hajiioannou; A K Stamou; S Kastrinakis; A J Bizaki; D E Kyrmizakis Journal: B-ENT Date: 2009 Impact factor: 0.082
Authors: Jonathan S Yoder; Susanne Straif-Bourgeois; Sharon L Roy; Thomas A Moore; Govinda S Visvesvara; Raoult C Ratard; Vincent R Hill; Jon D Wilson; Andrea J Linscott; Ron Crager; Natalia A Kozak; Rama Sriram; Jothikumar Narayanan; Bonnie Mull; Amy M Kahler; Chandra Schneeberger; Alexandre J da Silva; Mahendra Poudel; Katherine L Baumgarten; Lihua Xiao; Michael J Beach Journal: Clin Infect Dis Date: 2012-08-22 Impact factor: 9.079
Authors: Karen Head; Lee Yee Chong; Claire Hopkins; Carl Philpott; Martin J Burton; Anne G M Schilder Journal: Cochrane Database Syst Rev Date: 2016-04-26
Authors: Olavo de Godoy Mion; João Ferreira de Mello; Daniel Lorena Dutra; Nilvano Alves de Andrade; Washington Luiz de Cerqueira Almeida; Wilma Teresinha Anselmo-Lima; Leonardo Lopes Balsalobre Filho; Jair de Carvalho E Castro; Roberto Eustáquio Dos Santos Guimarães; Marcus Miranda Lessa; Sérgio Fabrício Maniglia; Roberto Campos Meireles; Márcio Nakanishi; Shirley Shizue Nagata Pignatari; Renato Roithmann; Fabrizio Ricci Romano; Rodrigo de Paula Santos; Marco César Jorge Dos Santos; Edwin Tamashiro Journal: Braz J Otorhinolaryngol Date: 2017-01-21